Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HIV Market Snapshot: Gilead's Biktarvy Set To Soar, But ViiV May Win In The End

Executive Summary

Gilead's Biktarvy (B/F/TAF) single tablet is poised to become a huge success, surpassing competitors in the HIV market by far, but the GlaxoSmithKline-backed ViiV Healthcare looks better positioned in the long run.

You may also be interested in...



10 Triumphant Drug Launches Of The Decade

The view from 2020: Scrip looks back at the most successful commercial launches of the decade.

Insurer Incentives For Lower-Cost HIV Drugs Not Seen As Significant Threat For Gilead, ViiV

UnitedHealthcare offers HIV-infected patients a financial incentive to switch to lower-cost therapy, including generic TDF, but analysts suspect the savings won’t be enough to encourage much switching away from Gilead’s single-tablet regimens.

ViiV/Janssen's Long-Acting Anti-HIV Injections Impress

A dual regimen consisting of long-acting injectable formulations of the integrase inhibitor cabotegravir and the nnRTI rilpivirine was as effective as the oral standard-of-care regimen of three drugs daily, in interim results from the ATLAS study.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel